Contrasting this evidence, other studies reported that HOXA1 downregulation is associated with a shorter survival rate [47], and its elevated expression could hinder tumor progression and enhance anti-tumor immune responses by reducing the immunosuppressive activity of myeloid-derived suppressor cells in lung cancer [48]. The gene discussed is HOXA1; the disease is lung cancer.